Waters invest in future generations
Waters has joined with Manchester?s Museum of Science and Industry (MOSI) to encourage schoolchildren to consider a career in science.
Waters has joined with Manchester’s Museum of Science and Industry (MOSI) to encourage schoolchildren to consider a career in science.
A team from Waters has recently visited a MOSI exhibition that reportedly featured the world’s first commercially available high-resolution mass spectrometer, which was developed by Waters in Manchester.
Tony Hill, MOSI chief executive, said, “Waters Corporation shares our vision to show science as an exciting and realistic career choice, and this is what makes them a perfect partner for MOSI and the Manchester Science Festival. We’re delighted that this kind of ground-breaking work is taking place in the Manchester region and it’s vitally important for MOSI to celebrate this.”
Liz Rae, corporate human resources vice-president for Waters Corporation, said, “The work we do with MOSI is very important in inspiring future scientists and can really capture the imagination of young people.”
Together, they will provide local schools with free, sponsored visits to the museum and host educational sessions.
For more information please visit ref="http://www.waters.com/waters/home.htm">www.waters.com
The Complexity of Oligonucleotide Separations
January 9th 2025Peter Pellegrinelli, Applications Specialist at Advanced Materials Technology (AMT) explains the complexity of oligonucleotide separations due to the unique chemical properties of these molecules. Issues such as varying length, sequence complexity, and hydrophilic-hydrophobic characteristics make efficient separations difficult. Separation scientists are addressing these challenges by modifying mobile phase compositions, using varying ion-pairing reagents, and exploring alternative separation modes like HILIC and ion-exchange chromatography. Due to these complexities, AMT has introduced the HALO® OLIGO column, which offers high-resolution, fast separations through its innovative Fused-Core® technology and high pH stability. Alongside explaining the new column, Peter looks to the future of these separations and what is next to come.
Metabolomics Analysis of Low Birth-Weight Infants Using UHPLC-MS/MS Following Lipid Emulsion
January 10th 2025A recent study aimed to directly compare the changes in serum metabolites among very low birth-rate (VLBW) infants following the administration of the soybean oil-based lipid emulsion and soybean oil, medium-chain triglycerides, olive oil, and fish oil (SMOF) lipid emulsion using untargeted metabolomics techniques.
Analyzing New Drug Modalities: An ISC 2024 Interview with Kelly Zhang
January 10th 2025At ISC 2024 in Liverpool, United Kingdom, LCGC International interviewed Kelly Zhang of Genentech about her work analyzing new drug modalities, such as mRNA, oligonucleotides, peptides, and cell and gene therapies.
